U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

An unassuming painkiller that most people have in their cupboard could help prevent the spread of cancer. Experts might have ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...